Structural basis of a shared antibody response to SARS-CoV-2
Open accessPublished version of a preprint
The DOI matches its Crossref record; 57 of the 57 references it cites were found in a registry or an index.
Abstract
Molecular understanding of neutralizing antibody responses to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) could accelerate vaccine design and drug discovery. We analyzed 294 anti-SARS-CoV-2 antibodies and found that immunoglobulin G heavy-chain variable region 3-53 (IGHV3-53) is the most frequently used IGHV gene for targeting the receptor-binding domain (RBD) of the spike protein. Co-crystal structures of two IGHV3-53-neutralizing antibodies with RBD, with or without Fab CR3022, at 2.33- to 3.20-angstrom resolution revealed that the germline-encoded residues dominate recognition of the angiotensin I converting enzyme 2 (ACE2)-binding site. This binding mode limits the IGHV3-53 antibodies to short complementarity-determining region H3 loops but accommodates light-chain diversity. These IGHV3-53 antibodies show minimal affinity maturation and high potency, which is promising for vaccine design. Knowledge of these structural motifs and binding mode should facilitate the design of antigens that elicit this type of neutralizing response.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“A number of public antibody responses have been reported for SARS-CoV-2, principal among these being VH3–53/VH3–66 and VH1–58 (VH3–30 is also found, but the antibodies are not potent neutralizers) (Yuan et al., 2020; Barnes et al., 2020; Dejnirattisai et al., 2021).”
From Antibody evasion by the P.1 strain of SARS-CoV-2 (2021) · cites this paper as Yuan et al., 2020
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Their engagement with the RBD is dictated by CDR-H1 and CDR-H2, while the CDR-H3 is characteristically short and makes rather few interactions”
From Antibody evasion by the P.1 strain of SARS-CoV-2 (2021) · cites this paper as Yuan et al., 2020
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
[20] Processing of X-ray diffraction data collected in oscillation mode
Otwinowski, Z., & Minor, W. (1997) · Methods in Enzymology · doi:10.1016/s0076-6879(97)76066-x · Cited by 33,475
Features and development of Coot
Emsley, P., Lohkamp, B., Scott, W. G., & Cowtan, K. (2010) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444910007493 · Cited by 29,915
PHENIX : a comprehensive Python-based system for macromolecular structure solution
Adams, P. D., Afonine, P. V., Bunkóczi, G., Chen, V. B., Davis, I. W., Echols, N., Headd, J. J., Hung, L.-W., Kapral, G. J., Grosse-Kunstleve, R. W., et al. (2010) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444909052925 · Cited by 23,716
A pneumonia outbreak associated with a new coronavirus of probable bat origin
Zhou, P., Yang, X.-L., Wang, X.-G., Hu, B., Zhang, L., Zhang, W., Si, H.-R., Zhu, Y., Li, B., Huang, C.-L., et al. (2020) · Nature · doi:10.1038/s41586-020-2012-7 · Cited by 21,969
Phaser crystallographic software
McCoy, A. J., Grosse-Kunstleve, R. W., Adams, P. D., Winn, M. D., Storoni, L. C., & Read, R. J. (2007) · Journal of Applied Crystallography · doi:10.1107/s0021889807021206 · Cited by 20,612
NMRPipe: A multidimensional spectral processing system based on UNIX pipes
Delaglio, F., Grzesiek, S., Vuister, G., Zhu, G., Pfeifer, J., & Bax, A. (1995) · Journal of Biomolecular NMR · doi:10.1007/bf00197809 · Cited by 15,965
Inference of Macromolecular Assemblies from Crystalline State
Krissinel, E., & Henrick, K. (2007) · Journal of Molecular Biology · doi:10.1016/j.jmb.2007.05.022 · Cited by 9,984
Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation
Wrapp, D., Wang, N., Corbett, K. S., Goldsmith, J. A., Hsieh, C.-L., Abiona, O., Graham, B. S., & McLellan, J. S. (2020) · Science · doi:10.1126/science.abb2507 · Cited by 8,897
PHENIX: a comprehensive Python-based system for macromolecular structure solution
Adams, P. D., Afonine, P. V., Bunkóczi, G., Chen, V. B., Davis, I. W., Echols, N., Headd, J. J., Hung, L.-W., Kapral, G. J., Grosse-Kunstleve, R. W., et al. (2012) · International Tables for Crystallography · doi:10.1107/97809553602060000865 · Cited by 7,334
Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor
Lan, J., Ge, J., Yu, J., Shan, S., Zhou, H., Fan, S., Zhang, Q., Shi, X., Wang, Q., Zhang, L., et al. (2020) · Nature · doi:10.1038/s41586-020-2180-5 · Cited by 5,983
Cited by
Items 201–300 of 597
Potent SARS-CoV-2 binding and neutralization through maturation of iconic SARS-CoV-1 antibodies
Rouet, R., Mazigi, O., Walker, G. J., Langley, D. B., Sobti, M., Schofield, P., Lenthall, H., Jackson, J., Ubiparipovic, S., Henry, J. Y., et al. (2021) · mAbs · doi:10.1080/19420862.2021.1922134 · Cited by 36
Apigenin analogues as SARS-CoV-2 main protease inhibitors: In-silico screening approach
Farhat, A., Hlima, H. B., Khemakhem, B., Halima, Y. B., Michaud, P., Abdelkafi, S., & Fendri, I. (2022) · Bioengineered · doi:10.1080/21655979.2022.2027181 · Cited by 43
“It was recently found that the main protease of this virus (M) plays a crucial role in SARS-CoV gene expression and replication [5].”
BackgroundSun, C., Kang, Y., Liu, Y.-T., Kong, X., Xu, H.-Q., Xiong, D., Xie, C., Liu, Y., Peng, S., Feng, G., et al. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-00910-6 · Cited by 39
“…a panel of neutralizing antibodies with available RBD-bound crystal structures, including S2-E12, Regdanvimab (or CT-P59), Regn10987, Regn10933, P2B-2F6, Fab2-15, S2-M11, S2-H14, COVA1-16, CB6, and CR3022, 9,50 – 57 and selected a high-resolution ACE2-RBD complex structure for interface analysis.”
BackgroundStructure-based neutralizing mechanisms for SARS-CoV-2 antibodies
Huang, Q., Han, X., & Yan, J. (2022) · Emerging Microbes & Infections · doi:10.1080/22221751.2022.2125348 · Cited by 41
Wang, Y., Lv, H., Teo, Q. W., Lei, R., Gopal, A. B., Ouyang, W. O., Yeung, Y.-H., Tan, T. J. C., Choi, D., Shen, I. R., et al. (2024) · Immunity · doi:10.1016/j.immuni.2024.07.022 · Cited by 47
Noy-Porat, T., Mechaly, A., Levy, Y., Makdasi, E., Alcalay, R., Gur, D., Aftalion, M., Falach, R., Ben‐Arye, S. L., Lazar, S., et al. (2021) · iScience · doi:10.1016/j.isci.2021.102479 · Cited by 36
Analysis of Glycosylation and Disulfide Bonding of Wild-Type SARS-CoV-2 Spike Glycoprotein
Zhang, S., Go, E. P., Ding, H., Anang, S., Kappes, J. C., Desaire, H., & Sodroski, J. (2021) · Journal of Virology · doi:10.1128/jvi.01626-21 · Cited by 42
“which recognizes open spike conformations with RBDs in the up position (12, 82, 83), binds FIG 15 Neutralization of viruses pseudotyped with S glycoprotein variants.”
BackgroundMethodZhu, T., Xiao, Y., Meng, X., Tang, L., Li, B., Zhao, Z., Tan, Q., Shan, H., Liu, L., & Huang, X. (2021) · Journal of Nanobiotechnology · doi:10.1186/s12951-021-01148-0 · Cited by 40
“CR3022 and B38 were isolated from a convalescent SARSCoV-1 patient and a SARS-CoV-2 patient, respectively [4, 5].”
BackgroundWindsor, I. W., Tong, P., Lavidor, O., Moghaddam, A. S., McKay, L. G. A., Gautam, A. K., Chen, Y., MacDonald, E. A., Yoo, D. K., Griffths, A., et al. (2022) · Science Immunology · doi:10.1126/sciimmunol.abo3425 · Cited by 39
Martinez, O. M., Bridges, N. D., Goldmuntz, E. A., & Pascual, V. (2020) · Nature Medicine · doi:10.1038/s41591-020-1140-9 · Cited by 38
Integrated single-cell analysis revealed immune dynamics during Ad5-nCoV immunization
Cao, Q., Wu, S., Xiao, C., Chen, S., Chi, X., Cui, X., Tang, H., Su, W., Zheng, Y., Zhong, J., et al. (2021) · Cell Discovery · doi:10.1038/s41421-021-00300-2 · Cited by 43
Enhanced SARS-CoV-2 Neutralization by Secretory IgA in vitro
Wang, Z., Lorenzi, J. C. C., Muecksch, F., Finkin, S., Viant, C., Gaebler, C., Cipolla, M., Hoffman, H.-H., Oliveira, T. Y., Oren, D. A., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.09.09.288555 · Cited by 35
An antibody targeting the N-terminal domain of SARS-CoV-2 disrupts the spike trimer
Suryadevara, N., Shiakolas, A. R., VanBlargan, L. A., Binshtein, E., Chen, R. E., Case, J. B., Kramer, K. J., Armstrong, E., Myers, L., Trivette, A., et al. (2022) · Journal of Clinical Investigation · doi:10.1172/jci159062 · Cited by 32
Structural and functional insights into the evolution of SARS-CoV-2 KP.3.1.1 spike protein
Feng, Z., Huang, J., Baboo, S., Diedrich, J. K., Bangaru, S., Paulson, J. C., Yates, J. R., Yuan, M., Wilson, I. A., & Ward, A. B. (2025) · Cell Reports · doi:10.1016/j.celrep.2025.115941 · Cited by 37
“19,30 To determine whether KP.3.1.1 or other S31Δ variants escape BD55-1205, we used BLI to measure binding affinities between spike proteins and the antibody binding fragment (Fab) (Figures 5G and S7).”
InfluentialBroadly neutralizing antibodies to SARS-related viruses can be readily induced in rhesus macaques
He, W., Yuan, M., Callaghan, S., Musharrafieh, R. G., Song, G., Silva, M., Beutler, N., Lee, W.-H., Yong, P., Torres, J. L., et al. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.abl9605 · Cited by 32
“For the human nAbs, the germline-encoded CDRH1 and CDRH2 both contribute substantially to RBD recognition (18, 22); the macaque nAbs predominantly rely on CDRH2 and less on CDRH1 (Fig.”
InfluentialZhou, X., Ma, F., Xie, J., Yuan, M., Li, Y., Shaabani, N., Zhao, F., Huang, D., Wu, N. C., Lee, C.-C. D., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109109 · Cited by 34
SARS-CoV-2 Variants, RBD Mutations, Binding Affinity, and Antibody Escape
Yang, L., Li, J., Guo, S., Hou, C., Liao, C., Shi, L., Ma, X., Jiang, S., Zheng, B., Fang, Y., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222212114 · Cited by 37
“The side chain of E is also very hydrophilic, according to the hydrophobicity scales [62].”
BackgroundFang, Y., Sun, P., Xie, X., Du, M., Du, F., Ye, J., Kalveram, B., Plante, J. A., Plante, K. S., Li, B., et al. (2022) · Science Immunology · doi:10.1126/sciimmunol.abp9962 · Cited by 30
“3 (16), an antibody known to compete with ACE2, was used as a positive control.”
InfluentialSARS-CoV-2 variants impact RBD conformational dynamics and ACE2 accessibility
Valério, M., Borges-Araújo, L., Melo, M. N., Lousa, D., & Soares, C. M. (2022) · Frontiers in Medical Technology · doi:10.3389/fmedt.2022.1009451 · Cited by 37
Yan, Q., Hou, R., Huang, X., Zhang, Y., He, P., Zhang, Y., Liu, B., Wang, Q., Rao, H., Chen, X., et al. (2022) · Emerging Microbes & Infections · doi:10.1080/22221751.2022.2140611 · Cited by 31
“1 [11], COVOX-222 [28], and rmAb23 [10], are known to maintain neutralizing activities to Delta variant”
BackgroundStructural basis of broad SARS-CoV-2 cross-neutralization by affinity-matured public antibodies
Sheward, D. J., Pushparaj, P., Das, H., Greaney, A. J., Kim, C., Kim, S., Hanke, L., Hyllner, E., Dyrdak, R., Lee, J., et al. (2024) · Cell Reports Medicine · doi:10.1016/j.xcrm.2024.101577 · Cited by 33
Song, G., Yuan, M., Liu, H., Capozzola, T., Lin, R. N., Torres, J. L., He, W., Musharrafieh, R., Dueker, K., Zhou, P.-P., et al. (2025) · Cell Reports · doi:10.1016/j.celrep.2025.115948 · Cited by 30
Sangesland, M., & Lingwood, D. (2021) · Vaccines · doi:10.3390/vaccines9020125 · Cited by 37
Anatomy of Omicron BA.1 and BA.2 neutralizing antibodies in COVID-19 mRNA vaccinees
Andreano, E., Paciello, I., Marchese, S., Donnici, L., Pierleoni, G., Piccini, G., Manganaro, N., Pantano, E., Abbiento, V., Pileri, P., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-31115-8 · Cited by 27
He, B., Liu, S., Xu, M., Hu, Y., Lv, K., Wang, Y., Ma, Y., Zhai, Y., Yue, X., Liu, L., et al. (2022) · Emerging Microbes & Infections · doi:10.1080/22221751.2022.2105261 · Cited by 32
Evolving antibody evasion and receptor affinity of the Omicron BA.2.75 sublineage of SARS-CoV-2
Wang, Q., Li, Z., Guo, Y., Mellis, I. A., Iketani, S., Liu, M., Yu, J., Valdez, R., Lauring, A. S., Sheng, Z., et al. (2023) · iScience · doi:10.1016/j.isci.2023.108254 · Cited by 27
“One of these mutations, F486S,disrupted a commoncation-p interaction with R97 of Brii-196 from VH3-53 gene class, 29 as well as the interactions with Y92 and W98 for S2E12.”
BackgroundA structure-function analysis shows SARS-CoV-2 BA.2.86 balances antibody escape and ACE2 affinity
Liu, C., Zhou, D., Dijokaite-Guraliuc, A., Supasa, P., Duyvesteyn, H. M. E., Ginn, H. M., Selvaraj, M., Mentzer, A. J., Das, R., de Silva, T. I., et al. (2024) · Cell Reports Medicine · doi:10.1016/j.xcrm.2024.101553 · Cited by 30
Structural basis of Omicron neutralization by affinity-matured public antibodies
Sheward, D. J., Pushparaj, P., Das, H., Kim, C., Kim, S., Hanke, L., Dyrdak, R., McInerney, G., Albert, J., Murrell, B., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.01.03.474825 · Cited by 30
Further antibody escape by Omicron BA.4 and BA.5 from vaccine and BA.1 serumPreprint
Tuekprakhon, A., Huo, J., Nutalai, R., Dijokaite-Guraliuc, A., Zhou, D., Ginn, H. M., Selvaraj, M., Liu, C., Mentzer, A. J., Supasa, P., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.05.21.492554 · Cited by 31
Structural Immunology of SARS ‐ CoV ‐2
Yuan, M., & Wilson, I. A. (2024) · Immunological Reviews · doi:10.1111/imr.13431 · Cited by 29
Human monoclonal antibodies targeting A35 protect from death caused by mpox
Fantin, R. F., Yuan, M., Park, S., Bozarth, B., Cohn, H., Ignacio, M. A., Earl, P. L., Civljak, A., Laghlali, G., Zhang, D., et al. (2025) · Cell · doi:10.1016/j.cell.2025.08.004 · Cited by 38
Generation of antigen-specific paired-chain antibodies using large language models
Wasdin, P. T., Johnson, N. V., Janke, A. K., Held, S., Marinov, T. M., Jordaan, G., Gillespie, R. A., Vandenabeele, L., Pantouli, F., Powers, O. C., et al. (2025) · Cell · doi:10.1016/j.cell.2025.10.006 · Cited by 44
Graham, C., Seow, J., Huettner, I., Khan, H., Kouphou, N., Acors, S., Winstone, H., Pickering, S., Galao, R. P., Lista, M. J., et al. (2021) · doi:10.1101/2021.02.03.429355 · Cited by 27
“Group 1 nAbs competed with a previously described SARS-CoV nAb CR3022 which binds an RBD site distal to the ACE2 receptor binding site (Yuan et al., 2020b; Yuan et al., 2020c) (classified Class 4 by Barnes et al (Barnes et al., 2020)).”
InfluentialGenetic determinants of IgG antibody response to COVID-19 vaccination
Bian, S., Guo, X., Yang, X., Wei, Y., Yang, Z., Cheng, S., Yan, J., Chen, Y., Chen, G., Du, X., et al. (2024) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2023.12.005 · Cited by 34
Watanabe, K., Watanabe, C., Honma, T., Tian, Y., Kawashima, Y., Kawashita, N., Takagi, T., & Fukuzawa, K. (2021) · The Journal of Physical Chemistry Letters · doi:10.1021/acs.jpclett.1c00663 · Cited by 27
SARS-CoV-2: Origin, Evolution, and Targeting Inhibition
Ning, S., Yu, B., Wang, Y., & Wang, F. (2021) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2021.676451 · Cited by 29
Shinnakasu, R., Sakakibara, S., Yamamoto, H. H., Wang, P.-H., Moriyama, S., Sax, N., Ono, C., Yamanaka, A., Adachi, Y., Onodera, T., et al. (2021) · The Journal of Experimental Medicine · doi:10.1084/jem.20211003 · Cited by 29
Yuan, M., Chen, X., Zhu, Y., Dong, X., Liu, Y., Qian, Z., Ye, L., & Liu, P. (2022) · Journal of Virology · doi:10.1128/jvi.00775-22 · Cited by 28
Ouyang, W. O., Tan, T. J. C., Lei, R., Song, G., Kieffer, C., Andrabi, R., Matreyek, K. A., & Wu, N. C. (2022) · Science Advances · doi:10.1126/sciadv.add7221 · Cited by 28
Scharf, L., Axelsson, H., Emmanouilidi, A., Mathew, N. R., Sheward, D. J., Leach, S., Isakson, P., Smirnov, I. V., Marklund, E., Miron, N., et al. (2023) · JCI Insight · doi:10.1172/jci.insight.165299 · Cited by 31
Zhao, F., Yuan, M., Keating, C., Shaabani, N., Limbo, O., Joyce, C., Woehl, J. L., Barman, S., Burns, A., Tran, Q., et al. (2023) · Science Signaling · doi:10.1126/scisignal.abk3516 · Cited by 28
“Iterative model building and refinement were performed in COOT (31, 33, 34) and PHENIX (35), respectively.”
MethodLubin, J. H., Markosian, C., Balamurugan, D., Ma, M. T., Chen, C.-H., Liu, D., Pasqualini, R., Arap, W., Burley, S. K., & Khare, S. D. (2023) · JCI Insight · doi:10.1172/jci.insight.168296 · Cited by 26
Barre, A., Damme, E. J. M. V., Simplicien, M., Benoist, H., & Rougé, P. (2020) · Marine Drugs · doi:10.3390/md18110543 · Cited by 29
Cross-Reactive SARS-CoV-2 Neutralizing Antibodies From Deep Mining of Early Patient Responses
Bullen, G., Galson, J. D., Hall, G., Villar, P., Moreels, L., Ledsgaard, L., Mattiuzzo, G., Bentley, E. M., Masters, E. W., Tang, D., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.678570 · Cited by 28
“Consistent with its antiviral potency, ION_360 binds to the ACE2 receptor binding motif (RBM) on the SARS-CoV-2 RBD, which is a feature reported for a number of antiviral antibodies (27, 36).”
BackgroundQiao, X., Qu, L., Guo, Y., & Hoshino, T. (2021) · The Journal of Physical Chemistry B · doi:10.1021/acs.jpcb.1c05997 · Cited by 25
Structural Biology of Nanobodies against the Spike Protein of SARS-CoV-2
Tang, Q., Owens, R. J., & Naismith, J. H. (2021) · Viruses · doi:10.3390/v13112214 · Cited by 24
“The picture that emerges is similar to the pattern for nanobody binding with human antibodies broadly falling into the four classes corresponding to epitopes that map to (i) the RBD-ACE-2 interface (Cluster 2; Classes 1 and 2), exemplified by REGN 10933 [62], (ii) the outer face of the RBD exemplified by S309 (Class 3…”
BackgroundImmunodominant antibody germlines in COVID-19
Andreano, E., & Rappuoli, R. (2021) · The Journal of Experimental Medicine · doi:10.1084/jem.20210281 · Cited by 24
Kramer, K. J., Johnson, N. V., Shiakolas, A. R., Suryadevara, N., Periasamy, S., Raju, N., Williams, J. K., Wrapp, D., Zost, S. J., Walker, L. M., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109784 · Cited by 27
Francino-Urdaniz, I. M., & Whitehead, T. A. (2021) · RSC Chemical Biology · doi:10.1039/d1cb00169h · Cited by 28
“32 Structures of IGHV3-53 nAbs CC12.”
BackgroundInfluentialAntibody-mediated immunity to SARS-CoV-2 spike
Errico, J. M., Adams, L. J., & Fremont, D. H. (2022) · Advances in immunology · doi:10.1016/bs.ai.2022.07.001 · Cited by 26
“3, C105, COVA2–04, and CV30, among others (Barnes, Jette, et al., 2020; Hurlburt et al., 2020; Wu, Yuan, et al., 2020; Wu, Wang, Shen, et al., 2020; Yuan et al., 2020).”
InfluentialXiong, H., Sun, H., Wang, S., Yuan, L., Liu, L., Zhu, Y., Zhang, J., Huang, Y., Qi, R., Jiang, Y., et al. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2204256119 · Cited by 21
Antibody and B Cell Responses to SARS-CoV-2 Infection and Vaccination: The End of the Beginning
Röltgen, K., & Boyd, S. D. (2023) · Annual Review of Pathology Mechanisms of Disease · doi:10.1146/annurev-pathmechdis-031521-042754 · Cited by 29
An integrated technology for quantitative wide mutational scanning of human antibody Fab libraries
Petersen, B. M., Kirby, M. B., Chrispens, K. M., Irvin, O. M., Strawn, I. K., Haas, C. M., Walker, A. M., Baumer, Z. T., Ulmer, S. A., Ayala, E., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-48072-z · Cited by 24
The S2 subunit of spike encodes diverse targets for functional antibody responses to SARS-CoV-2
Guenthoer, J., Garrett, M. E., Lilly, M., Depierreux, D., Ruiz, F., Chi, M., Stoddard, C. I., Chohan, V., Yaffe, Z. A., Sung, K., et al. (2024) · PLoS Pathogens · doi:10.1371/journal.ppat.1012383 · Cited by 30
Sitthiyotha, T., & Chunsrivirot, S. (2021) · Scientific Reports · doi:10.1038/s41598-021-94873-3 · Cited by 27
Structural mechanism of SARS-CoV-2 neutralization by two murine antibodies targeting the RBD
Errico, J. M., Zhao, H., Chen, R. E., Liu, Z., Case, J. B., Ma, M., Schmitz, A. J., Rau, M., Fitzpatrick, J. A. J., Shi, P., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109881 · Cited by 23
“3, C105, COVA2-04, and CV30 (Figure 3A, red group) (Barnes et al., 2020a; Hurlburt et al., 2020; Shi et al., 2020; Wu et al., 2020a, 2020b; Yuan et al., 2020b).”
InfluentialMorinaga, Y., Tani, H., Terasaki, Y., Nomura, S., Kawasuji, H., Shimada, T., Igarashi, E., Saga, Y., Yoshida, Y., Yasukochi, R., et al. (2021) · Microbiology Spectrum · doi:10.1128/spectrum.00560-21 · Cited by 23
“While not all antibodies against the RBD are neutralizing (6, 7), these test values may reflect the proportion of antibodies that protect against SARS-CoV-2 (8, 9).”
BackgroundRapid identification of neutralizing antibodies against SARS-CoV-2 variants by mRNA display
Tanaka, S., Olson, C. A., Barnes, C. O., Higashide, W., Gonzalez, M. R., Taft, J. D., Richardson, A., Martín-Fernández, M., Bogunovic, D., Gnanapragasam, P. N. P., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.110348 · Cited by 20
“Previous immunoglobulin heavy chain variable region (IGHV) gene analysis identified distinct IGVH genes (e.g. 1–53) that were more likely to produce potent RBD-binding nAbs (Dejnirattisai et al., 2021; Robbiani et al., 2020; Yuan et al., 2020) within the human antibody repertoire.”
Ma, H., Guo, Y., Tang, H., Tseng, C.-T. K., Wang, L., Zong, H., Wang, Z., He, Y., Chang, Y., Wang, S., et al. (2022) · Cell Discovery · doi:10.1038/s41421-022-00381-7 · Cited by 23
Yu, H., Liu, B., Zhang, Y., Gao, X., Wang, Q., Xiang, H., Peng, X., Xie, C., Wang, Y., Hu, P., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-36761-0 · Cited by 27
SARS-CoV-2 antibodies recognize 23 distinct epitopic sites on the receptor binding domain
Jiang, J., Boughter, C. T., Ahmad, J., Natarajan, K., Boyd, L. F., Meier-Schellersheim, M., & Margulies, D. H. (2023) · Communications Biology · doi:10.1038/s42003-023-05332-w · Cited by 24
“Previous work identi fi ed the over-represented public class of mAbs encoded by IGHV3-53 and IGHV3-66 that neutralize the spike 45,49,50 .”
Insights into next generation sequencing guided antibody selection strategies
Erasmus, M. F., Ferrara, F., D’Angelo, S., Spector, L. P., Leal‐Lopes, C., Teixeira, A. A. R., Sørensen, J., Nagpal, S., Perea‐Schmittle, K., Choudhary, A. K., et al. (2023) · Scientific Reports · doi:10.1038/s41598-023-45538-w · Cited by 24
“Although a mixed pool of germline scaffolds was used in the campaign 1 , most of the selected diversity belonged to the IGHV1-24::IGKV1-12 germline, with a modest representation from other VH/VL pairs, highlighting a potential target-driven preference for specific scaffolds 13 (Fig.”
The SARS-CoV-2 neutralizing antibody response to SD1 and its evasion by BA.2.86
Stuart, D., Liu, C., Das, R., Dijokaite-Guraliuc, A., Zhou, D., Duyvesteyn, H. M. E., Mentzer, A. J., Supasa, P., Selvaraj, M., Ritter, T. G., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-46982-6 · Cited by 27
“Most potent anti-RBD mAbs bind on or in close proximity to the receptor binding motif 9 – 11 , blocking the interaction of RBD with the cellular SARS-CoV-2 receptor, angiotensin-converting enzyme 2 (ACE2) 12 , although a few bind elsewhere and may function to destabilize the S trimer 13 – 15 .”
Effect of RBD mutations in spike glycoprotein of SARS-CoV-2 on neutralizing IgG affinityPreprint
Hayashi, T., Yaegashi, N., & Konishi, I. (2021) · Research Square · doi:10.1101/2021.01.28.21250577 · Cited by 24
“We investigated the virological characteristics of this SARS-CoV-2 mutant (Y453F) using three-dimensional protein structural analysis (Spanner program, MOE protein program and Cn3D macromolecular structure viewer) [5,6].”
MethodModeling coronavirus spike protein dynamics: implications for immunogenicity and immune escape
Kunkel, G., Madani, M., White, S. J., Verardi, P. H., & Tarakanova, A. (2021) · Biophysical Journal · doi:10.1016/j.bpj.2021.11.009 · Cited by 23
Humoral immunity to SARS-CoV-2 elicited by combination COVID-19 vaccination regimens
Wang, Z., Muecksch, F., Münn, F., Cho, A., Zong, S., Raspe, R., Ramos, V., Johnson, B., Tanfous, T. B., DaSilva, J., et al. (2022) · The Journal of Experimental Medicine · doi:10.1084/jem.20220826 · Cited by 24
“Epitopes and neutralizing breadth SARS-CoV-2 infection and vaccination elicit anti-RBD antibodies that target four structurally defined classes of epitopes on the RBD (Barnes et al., 2020; Muecksch et al., 2022; Muecksch et al., 2021; Wang et al., 2021c; Yuan et al., 2020).”
BackgroundZhang, Y., Sun, J., Zheng, J. H., Li, S., Rao, H., Dai, J., Zhang, Z., Wang, Y., Liu, D., Chen, Z., et al. (2023) · Advanced Science · doi:10.1002/advs.202303366 · Cited by 26
Kotaki, R., Moriyama, S., Oishi, S., Onodera, T., Adachi, Y., Sasaki, E., Ishino, K., Morikawa, M., Takei, H., Takahashi, H., et al. (2024) · Science Translational Medicine · doi:10.1126/scitranslmed.adp9927 · Cited by 29
Hangyu, W., Li, P., Shen, J., Wang, H., Linmiao, W., Kangning, H., Yichen, S., Wang, S., & Wang, C. (2024) · Journal of Microbiology and Biotechnology · doi:10.4014/jmb.2403.03008 · Cited by 26
“Abidor is able to bind S proteins to block their trimerization and thus inhibit SARS-CoV-2 invasion into host cells [31, 32]. nAbs were also used to inhibit SARS-CoV-2 infection by blocking the binding of S proteins to host cell surface receptors [33-35].”
MethodFrom Structural Studies to HCV Vaccine Design
Yechezkel, I., Law, M., & Tzarum, N. (2021) · Viruses · doi:10.3390/v13050833 · Cited by 25
Seow, J., Graham, C., Hallett, S. R., Lechmere, T., Maguire, T. J. A., Huettner, I., Cox, D., Khan, H., Pickering, S., Roberts, R., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.110757 · Cited by 18
“…identified and characterized (Figure 4E) (Barnes et al., 2020; Yuan et al., 2020b). nAbs that neutralize by binding to the receptor-binding motif (RBM) (equivalent to RBD class 1) (Barnes et al., 2020; Dejnirattisai et al., 2021; Yuan et al., 2020a) commonly use the VH3-53 or VH3-66 germ lines.”
InfluentialLong, Y., Sun, J., Song, T., Liu, T., Tang, F., Zhang, X., Ding, L., Miao, Y., Zhu, W., Pan, X., et al. (2022) · Cell Discovery · doi:10.1038/s41421-021-00370-2 · Cited by 25
Antibody evolution to SARS-CoV-2 after single-dose Ad26.COV2.S vaccine in humans
Cho, A., Muecksch, F., Wang, Z., Tanfous, T. B., DaSilva, J., Raspe, R., Johnson, B., Bednarski, E., Ramos, V., Schaefer-Babajew, D. J., et al. (2022) · The Journal of Experimental Medicine · doi:10.1084/jem.20220732 · Cited by 22
“Epitope specificity of RBD-binding antibodies mRNA vaccination elicits anti-RBD antibodies that target four structurally defined classes of epitopes on the RBD (Barnes et al., 2020a; Muecksch et al., 2021, 2022; Wang et al., 2021b; Yuan et al., 2020).”
BackgroundZhang, Y., Li, Q., Luo, L., Duan, C., Shen, J., & Wang, Z. (2023) · Biotechnology Advances · doi:10.1016/j.biotechadv.2023.108143 · Cited by 24
Mechanistic basis for potent neutralization of Sin Nombre hantavirus by a human monoclonal antibody
Stass, R., Engdahl, T. B., Chapman, N. S., Wolters, R. M., Handal, L. S., Diaz, S. M., Crowe, J. E., & Bowden, T. A. (2023) · Nature Microbiology · doi:10.1038/s41564-023-01413-y · Cited by 22
Huang, R., Jenkins, G. W., Kim, Y., Stanfield, R. L., Singh, A., Martinez‐Yamout, M. A., Kroon, G. J. A., Torres, J. L., Jackson, A. M., Kelley, A., et al. (2023) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2303455120 · Cited by 25
Paschold, L., Klee, B., Gottschick, C., Willscher, E., Diexer, S., Schultheiß, C., Simnica, D., Sedding, D., Girndt, M., Gekle, M., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.876306 · Cited by 21
“(4), COVID-19 generates both germinal center and extrafollicular B cell responses in unvaccinated individuals – depending on the severity of infection - that converge on B cells expressing antigen receptors with preferential immunoglobulin heavy chain variable-joining gene (IGHV-J) usage (1, 5-12).”
BackgroundA Potent and Protective Human Neutralizing Antibody Against SARS-CoV-2 Variants
Shan, S., Mok, C. K., Zhang, S., Lan, J., Li, J., Yang, Z., Wang, R., Cheng, L., Fang, M., Aw, Z. Q., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.766821 · Cited by 21
“Through structure and functional characterization, the RBD-specific antibodies were classified into four major categories (8, 10): class I antibodies, which are encoded by the VH3-53 gene segment with short CDRH3 loops, block ACE2 and bind only to “up” RBDs; class II neutralizing antibodies include ACE2-blocking neutr…”
BackgroundBeyond the new normal: Assessing the feasibility of vaccine-based suppression of SARS-CoV-2
Stoddard, M., Sarkar, S., Lin, Y., Nolan, R. P., White, D. E., White, L. F., Hochberg, N. S., & Chakravarty, A. (2021) · PLoS ONE · doi:10.1371/journal.pone.0254734 · Cited by 22
Glycosylation and Serological Reactivity of an Expression-enhanced SARS-CoV-2 Viral Spike Mimetic
Chawla, H., Jossi, S. E., Faustini, S. E., Samsudin, F., Allen, J. D., Watanabe, Y., Newby, M. L., Marcial‐Juárez, E., Lamerton, R. E., McLellan, J. S., et al. (2021) · Journal of Molecular Biology · doi:10.1016/j.jmb.2021.167332 · Cited by 21
Ehling, R. A., Weber, C. R., Mason, D. M., Friedensohn, S., Wagner, B., Bieberich, F., Kapetanovic, E., Vazquez-Lombardi, R., Roberto, R. B. D., Hong, K., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.110242 · Cited by 28
“Given that CR3022 binds a cryptic epitope that requires a conformational change of the RBD (Yuan et al., 2020a), binding of another antibody may reduce the stability of such a change.”
BackgroundInfluentialBozdaganyan, M. E., Sokolova, O. S., Шайтан, К. В., Kirpichnikov, M. P., & Orekhov, P. S. (2022) · Viruses · doi:10.3390/v14020295 · Cited by 21
Evidence of antigenic drift in the fusion machinery core of SARS-CoV-2 spike
Tan, T. J. C., Verma, A. K., Odle, A. E., Lei, R., Meyerholz, D. K., Matreyek, K. A., Perlman, S. M., Wong, L.-Y. R., & Wu, N. C. (2024) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2317222121 · Cited by 24
“3 (25, 26).”
SARS-CoV-2 JN.1 variant evasion of IGHV3-53/3-66 B cell germlines
Paciello, I., Maccari, G., Pierleoni, G., Perrone, F., Realini, G., Troisi, M., Anichini, G., Cusi, M. G., Rappuoli, R., & Andreano, E. (2024) · Science Immunology · doi:10.1126/sciimmunol.adp9279 · Cited by 24
Effect of RBD mutation (Y453F) in spike glycoprotein of SARS-CoV-2 on neutralizing antibody affinityPreprint
Hayashi, T., Yaegashi, N., & Konishi, I. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.11.27.401893 · Cited by 21
Buchwald, P. (2022) · Frontiers in Drug Discovery · doi:10.3389/fddsv.2022.898035 · Cited by 21
“In fact, the spike protein is the principal target of nAbs generated following infection by SARS-CoV-2, with the majority of those identified so far recognizing epitopes within the receptor-binding domain (RBD) that binds ACE2 (Sui et al., 2014; Lv et al., 2020; Wang et al., 2020; Wu et al., 2020; Yuan et al., 2020).”
BackgroundGadush, M., Sautto, G. A., Chandrasekaran, H., Bensussan, A., Ross, T. M., Ippolito, G. C., & Person, M. D. (2022) · Journal of Proteome Research · doi:10.1021/acs.jproteome.1c00913 · Cited by 20
Li, X., Pan, Y., Yin, Q., Wang, Z., Shan, S., Zhang, L., Yu, J., Qu, Y., Sun, L., Gui, F., et al. (2022) · Cell Discovery · doi:10.1038/s41421-022-00449-4 · Cited by 20
Age-dependent acquisition of pathogenicity by SARS-CoV-2 Omicron BA.5
Imbiakha, B., Ezzatpour, S., Buchholz, D. W., Sahler, J., Ye, C., Olarte‐Castillo, X. A., Zou, A., Kwas, C. T., O’Hare, K., Choi, A., et al. (2023) · Science Advances · doi:10.1126/sciadv.adj1736 · Cited by 24
“SARS-CoV-2 S protein has been the major target for vaccines and monoclonal antibody treatments (9, 10).”
BackgroundThe ACE2-binding Interface of SARS-CoV-2 Spike Inherently Deflects Immune Recognition
Hattori, T., Koide, A., Noval, M. G., Panchenko, T., Romero, L. A., Teng, K. W., Tada, T., Landau, N. R., Stapleford, K. A., & Koide, S. (2020) · Journal of Molecular Biology · doi:10.1016/j.jmb.2020.166748 · Cited by 21
“24 We first performed selection for antibodies against the spike protein and the RBD in an unbiased manner, that is, we did not incorporate steps that might bias the recovery of antibodies binding to different epitopes (Figure 3(A)).”
NMR Based SARS-CoV-2 Antibody Screening
Schoenle, M. V., Li, Y., Yuan, M., Clarkson, M. W., Wilson, I. A., Peti, W., & Page, R. (2021) · Journal of the American Chemical Society · doi:10.1021/jacs.1c03945 · Cited by 19
Yang, M., Li, J., Huang, Z., Li, H., Wang, Y., Wang, X., Kang, S., Huang, X., Wu, C., Liu, T., et al. (2021) · Microbiology Spectrum · doi:10.1128/spectrum.01352-21 · Cited by 21
Chernyshev, M., Sakharkar, M., Connor, R. I., Dugan, H. L., Sheward, D. J., Rappazzo, C. G., Stålmarck, A., Forsell, M. N. E., Wright, P. F., Corcoran, M., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-37972-1 · Cited by 17
Antibody sequence determinants of viral antigen specificity
Abu-Shmais, A. A., Vukovich, M. J., Wasdin, P. T., Suresh, Y. P., Marinov, T. M., Rush, S. A., Gillespie, R. A., Sankhala, R. S., Choe, M., Joyce, M. G., et al. (2024) · mBio · doi:10.1128/mbio.01560-24 · Cited by 19
Chang, M., Ke, H., Coherd, C. D., Wang, Y., Mashima, K., Kastrunes, G. M., Huang, C., & Marasco, W. A. (2022) · EBioMedicine · doi:10.1016/j.ebiom.2022.104025 · Cited by 22
Shared N417-Dependent Epitope on the SARS-CoV-2 Omicron, Beta, and Delta Plus Variants
Moyo-Gwete, T., Madzivhandila, M., Mkhize, N. N., Kgagudi, P., Ayres, F., Lambson, B. E., Manamela, N. P., Richardson, S. I., Makhado, Z., van der Mescht, M. A., et al. (2022) · Journal of Virology · doi:10.1128/jvi.00558-22 · Cited by 20
“Overall, these data suggest that the 084-7D MAb is dependent on the N417 residue present in the Beta RBD. MAb 084-7D exhibits Fc effector functionality, particularly against the Beta variant.”
BackgroundInfluentialThe Diagnostic and Prognostic Potential of the B-Cell Repertoire in Membranous Nephropathy
Su, Z., Jin, Y., Zhang, Y., Guan, Z., Li, H., Chen, X., Xie, C., Zhang, C., Liu, X., Li, P., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.635326 · Cited by 24
“analyzed 294 antiSARS-CoV-2 antibodies and found that IGHV3-53 is the most frequently used IGHV gene for targeting the receptor-binding domain of the spike protein (33).”
Ultrapotent neutralizing antibodies against SARS-CoV-2 with a high degree of mutation resistance
Zou, J., Li, L., Zheng, P., Liang, W., Hu, S., Zhou, S., Wang, Y., Zhao, J., Yuan, D., Liu, L., et al. (2022) · Journal of Clinical Investigation · doi:10.1172/jci154987 · Cited by 22
“A previous report showed that Ig variable region 3-53 (IGHV3-53) was the most frequently used region of the immunoglobulin heavy chain (IGVH) gene of RBD binders (21), but our spike binders showed a slightly different usage of IGHVs.”
Tian, X., Zhu, X., Song, W., Yang, Z., Wu, Y., & Ying, T. (2022) · Emerging Microbes & Infections · doi:10.1080/22221751.2022.2063074 · Cited by 17
Upadhyay, V., Patrick, C., Lucas, A., & Mallela, K. M. G. (2022) · Biochemistry · doi:10.1021/acs.biochem.2c00132 · Cited by 19
Metadata
- Authors
- Yuan, M., Liu, H., Wu, N. C., Lee, C.-C. D., Zhu, X., Zhao, F., Huang, D., Yu, W., Hua, Y., Tien, H., Rogers, T. F., Landais, E., Sok, D., Jardine, J. G., Burton, D. R., & Wilson, I. A.
- Affiliations
- Scripps Research Institute (US)
- Corresponding author
- Wilson, Ian A.
- ORCID
- Venue
- Science
- Published
- 2020-08-28
- Volume
- 369
- Issue
- 6507
- Pages
- 1119-1123
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- PMC
- PMC7402627
- OpenAlex
- W3041564586
- Cited by
- 589
- References
- 53
- Citations by year
- 2026: 33 · 2025: 48 · 2024: 55 · 2023: 64 · 2022: 133 · 2021: 203 · 2020: 51
- FWCI
- 14.89
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Science (publishedVersion, cc-by)
- bioRxiv (Cold Spring Harbor Laboratory) (acceptedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- OSTI OAI (U.S. Department of Energy Office of Scientific and Technical Information) (submittedVersion, cc-by)
- PubMed Central (submittedVersion, cc-by)
- Funders
- National Institutes of Health (K99 AI139445, UM1 AI44462)
- Bill and Melinda Gates Foundation (OPP1170236)
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › vaccines and immunoinformatics approaches
- Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
- Keywords
- SARS-CoV-2, neutralizing antibodies, receptor binding domain, spike protein, ACE2 binding site, co-crystal structure, germline antibodies, affinity maturation, vaccine design, antibody structure
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.